Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

pembrolizumab 110Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 50Cyclophosphamide 50Paclitaxel 48durvalumab 38Radiation 37Gemcitabine 37olaparib 32Rituximab 32Etoposide 32Dexamethasone 32Doxorubicin 30Docetaxel 30atezolizumab 28Lenalidomide 27Ipilimumab 27Taxes 26Pemetrexed 25Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Radiotherapy, Intensity-Modulated 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × polatuzumab vedotin × 90 days × Clear all
NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Completed
42 enrolled 10 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting
208 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
5 enrolled 13 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡